Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 2/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.67 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.67 |
| ▸ | DRD2 | P14416 | 6/20 | 0.65 |
| ▸ | HTR2A | P28223 | 6/20 | 0.65 |
| ▸ | HTR2C | P28335 | 5/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852369 | 0.88 | SIGMAR1 (0.63) | ADRA1DADRA1AADRA1BDRD2HTR2A | |
| SCHEMBL19852225 | 0.79 | HTR2A (1.00) | ADRA1DADRA1AADRA1BDRD2HTR2A | |
| SCHEMBL19852228 | 0.79 | HTR2A (0.71) | ADRA1DADRA1AADRA1BDRD2HTR2A | |
| SCHEMBL8010281 | 0.78 | DRD2 (0.74) | ADRA1DADRA1AADRA1BDRD2HTR2A | |
| SCHEMBL8576957 | 0.76 | DRD2 (0.67) | ADRA1DADRA1AADRA1BDRD2HTR2A | |
| SCHEMBL19838782 | 0.76 | HTR2A (0.71) | ADRA1DADRA1AADRA1BDRD2HTR2A | |
| SCHEMBL19838801 | 0.76 | HTR2A (0.71) | ADRA1DADRA1AADRA1BDRD2HTR2A | |
| SCHEMBL5317315 | 0.75 | HTR2A (0.64) | ADRA1DADRA1AADRA1BDRD2HTR2A | |
| SCHEMBL7439064 | 0.73 | DRD2 (0.83) | ADRA1DADRA1AADRA1BDRD2HTR2A | |
| SCHEMBL23926326 | 0.73 | SIGMAR1 (0.79) | DRD2KCNH2SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | ADRA1D 250/4885ADRA1A 330/4885ADRA1B 287/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | ADRA1D 250/4885ADRA1A 330/4885ADRA1B 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.